SALVETTI, CHIARA
SALVETTI, CHIARA
BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE
Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells
2019-01-01 Todaro Maria, Griggio Valentina, Salvetti Chiara, Riganti Chiara, Landesman Yosef, Boccadoro Mario, Vitale Candida, Coscia Marta
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells
2020-01-01 Vitale C, Todaro M, Griggio V, Salvetti C, Riganti C, Landesman Y, Boccadoro M, Coscia M.
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia
2019-01-01 Griggio V, Vitale C, Salvetti C, Mauro FR, Pietrasanta D, Vincelli ID, Scarfo L, Del Poeta G, Gaidano G, Gattei V, Foà R, Boccadoro M, Coscia M
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia
2018-01-01 Griggio V, Vitale C, Todaro M, Mauro FR, Salvetti C, Pietrasanta D, Vincelli ID, Scarfo L, Del Poeta G, Gaidano G, Gattei V, Foà R, Boccadoro M, Coscia M
Modulation of Phenotypic and Functional Features of Immune Cells in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib
2020-01-01 Perutelli F, Griggio V, Vitale C, Mauro FR, Salvetti C, Boccellato E, Pietrasanta D, Vincelli ID, Ghia P, Del Poeta G, Gaidano G, Gattei V, Foà R, Boccadoro M, Coscia M
Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs
2019-01-01 Vitale C, Salvetti C, Griggio V, Scamuffa MC, Zamprogna G, Visentin A, Cassin R, Laurenti L, Murru R, Rivela P, Marchetti M, Gentile M, Pennese E, Reda G, Trentin L, Tedeschi A, Mauro FR, Foà R, Boccadoro M, Coscia M
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET
2018-01-01 Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Salvetti, C; Bomben, R; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Omede, P; Bonello, L; Kodipad, AA; Laurenti, L; Del Poeta, G; Mauro, FR; Bernardi, R; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target
2018-01-01 Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target
2020-01-01 Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omedé P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target
2018-01-01 Vitale C, Griggio V, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE
2018-01-01 Todaro, M; Griggio, V; Vitale, C; Salvetti, C; Riganti, C; Boccadoro, M; Coscia, M
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells
2019-01-01 Vitale, Candida; Todaro, Maria; Griggio, Valentina; Salvetti, Chiara; Riganti, Chiara; Landesman, Yosef; Boccadoro, Mario; Coscia, Marta
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance
2016-01-01 Todaro, M; Griggio, V; Vitale, C; Salvetti, C; Riganti, C; Boccadoro, M; Landesman, Y; Coscia, M
Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights
2020-01-01 Salvetti C, Vitale C, Griggio V, Drandi D, Bonello L, Cavallo F, Bomben R, Gattei V, Zamò A, Coscia M
TARGETING HIF-1 AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER TUMOR-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2017-01-01 Vitale, C; Griggio, V; Todaro, M; Riganti, C; Salaroglio, IC; Salvetti, C; Rigoni, M; Foglietta, M; Castella, B; Boccadoro, M; Massaia, M; Coscia, M
TARGETING HIF-1A AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2017-01-01 Vitale, C; Griggio, V; Todaro, M; Riganti, C; Salaroglio, IC; Salvetti, C; Rigoni, M; Foglietta, M; Castella, B; Boccadoro, M; Massaia, M; Coscia, M
TARGETING THE CXCR4 DOWNSTREAM SIGNALLING PATHWAYS TO REVERSE MICROENVIRONMENT PROTECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
2016-01-01 Vitale, C; Griggio, V; Todaro, M; Riganti, C; Salaroglio, IC; Salvetti, C; Rigoni, M; Foglietta, M; Castella, B; Boccadoro, M; Massaia, M; Coscia, M
The CXCR4 downstream signaling pathways in chronic lymphocytic leukemia: a target to reverse microenvironment protection
2016-01-01 Vitale C, Griggio V, Todaro M, Riganti C, Salaroglio IC, Salvetti C, Rigoni M, Foglietta M, Castella B, Boccadoro M, Massaia M, Coscia M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells | 2019 | Todaro Maria, Griggio Valentina, Salvetti Chiara, Riganti Chiara, Landesman Yosef, Boccadoro Mario, Vitale Candida, Coscia Marta | |
| Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells | 2020 | Vitale C, Todaro M, Griggio V, Salvetti C, Riganti C, Landesman Y, Boccadoro M, Coscia M. | |
| Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia | 2019 | Griggio V, Vitale C, Salvetti C, Mauro FR, Pietrasanta D, Vincelli ID, Scarfo L, Del Poeta G, Gaidano G, Gattei V, Foà R, Boccadoro M, Coscia M | |
| Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia | 2018 | Griggio V, Vitale C, Todaro M, Mauro FR, Salvetti C, Pietrasanta D, Vincelli ID, Scarfo L, Del Poeta G, Gaidano G, Gattei V, Foà R, Boccadoro M, Coscia M | |
| Modulation of Phenotypic and Functional Features of Immune Cells in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib | 2020 | Perutelli F, Griggio V, Vitale C, Mauro FR, Salvetti C, Boccellato E, Pietrasanta D, Vincelli ID, Ghia P, Del Poeta G, Gaidano G, Gattei V, Foà R, Boccadoro M, Coscia M | |
| Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs | 2019 | Vitale C, Salvetti C, Griggio V, Scamuffa MC, Zamprogna G, Visentin A, Cassin R, Laurenti L, Murru R, Rivela P, Marchetti M, Gentile M, Pennese E, Reda G, Trentin L, Tedeschi A, Mauro FR, Foà R, Boccadoro M, Coscia M | |
| REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET | 2018 | Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Salvetti, C; Bomben, R; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Omede, P; Bonello, L; Kodipad, AA; Laurenti, L; Del Poeta, G; Mauro, FR; Bernardi, R; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M | |
| Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target | 2018 | Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M | |
| Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target | 2020 | Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omedé P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M | |
| Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target | 2018 | Vitale C, Griggio V, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M | |
| SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE | 2018 | Todaro, M; Griggio, V; Vitale, C; Salvetti, C; Riganti, C; Boccadoro, M; Coscia, M | |
| Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells | 2019 | Vitale, Candida; Todaro, Maria; Griggio, Valentina; Salvetti, Chiara; Riganti, Chiara; Landesman, Yosef; Boccadoro, Mario; Coscia, Marta | |
| Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance | 2016 | Todaro, M; Griggio, V; Vitale, C; Salvetti, C; Riganti, C; Boccadoro, M; Landesman, Y; Coscia, M | |
| Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights | 2020 | Salvetti C, Vitale C, Griggio V, Drandi D, Bonello L, Cavallo F, Bomben R, Gattei V, Zamò A, Coscia M | |
| TARGETING HIF-1 AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER TUMOR-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA | 2017 | Vitale, C; Griggio, V; Todaro, M; Riganti, C; Salaroglio, IC; Salvetti, C; Rigoni, M; Foglietta, M; Castella, B; Boccadoro, M; Massaia, M; Coscia, M | |
| TARGETING HIF-1A AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA | 2017 | Vitale, C; Griggio, V; Todaro, M; Riganti, C; Salaroglio, IC; Salvetti, C; Rigoni, M; Foglietta, M; Castella, B; Boccadoro, M; Massaia, M; Coscia, M | |
| TARGETING THE CXCR4 DOWNSTREAM SIGNALLING PATHWAYS TO REVERSE MICROENVIRONMENT PROTECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS | 2016 | Vitale, C; Griggio, V; Todaro, M; Riganti, C; Salaroglio, IC; Salvetti, C; Rigoni, M; Foglietta, M; Castella, B; Boccadoro, M; Massaia, M; Coscia, M | |
| The CXCR4 downstream signaling pathways in chronic lymphocytic leukemia: a target to reverse microenvironment protection | 2016 | Vitale C, Griggio V, Todaro M, Riganti C, Salaroglio IC, Salvetti C, Rigoni M, Foglietta M, Castella B, Boccadoro M, Massaia M, Coscia M |